Search Results - "PALDANIUS, PAIVI M."

918-P: Predicting the Onset of APECED Diabetes by PALDANIUS, PAIVI M., MAKITIE, OUTI, LAAKSO, SAILA

“…Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare monogenic autosomal recessive disorder and diabetes (DM) one of…”
Get full text

1512-PUB: Glucose Removal Rate in Patients with APECED by SANDINI, ERIK R., LAAKSO, SAILA, MAKITIE, OUTI, PALDANIUS, PAIVI M.

“…Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED or APS-1) is a rare autosomal recessive disorder and diabetes (DM) is one of…”
Get full text

963-P: Near-Infrared Device for Diabetes Screening—ANODE01 Study by CHOUDHARY, PRATIK, LAZARO-PACHECO, DANIELA, SALTER, JOHN E., PALDANIUS, PAIVI M.

“…Background: Diabetes mellitus (DM) screening is currently complex, inefficient and requires resource-intensive, invasive sampling. Development of affordable,…”
Get full text

749-P: Clinically Relevant Predictors of Cardiovascular Events: Exploratory Analysis from the VERIFY Study of Initial Treatment of Type 2 Diabetes Mellitus by MATTHEWS, DAVID R., DEL PRATO, STEFANO, PALDANIUS, PAIVI M., BADER, GIOVANNI

“…The VERIFY study of primary treatment in type 2 diabetes mellitus (T2DM) , showed delayed glycemic failure (HbA1c ≥7.0% at two consecutive scheduled visits…”
Get full text

986-P: Near-Infrared Device for Screening of Diabetes—ANODE02 Study by XAVIER COS, FRANCESC, LAZARO-PACHECO, DANIELA, SALTER, JOHN E., PALDANIUS, PAIVI M.

“…Background: Currently, screening for diabetes mellitus (DM) can be complex, inefficient and often resource-intensive with invasive sampling. Affordable…”
Get full text

94-LB: Long-Term Clinical Benefits of Early Combination Approach in Latin American Subpopulation of VERIFY Study by VENCIO, SERGIO, MANOSALVA, JUAN, MATHIEU, CHANTAL, PROOT, PIETER, PALDANIUS, PAIVI M.

“…The VERIFY study showed long-term clinical benefits of the early combination therapy of vildagliptin with metformin (EC) vs. traditional stepwise approach…”
Get full text

669-P: Prandial Insulin Secretion in the VERIFY Study by PALDANIUS, PAIVI M., MATTHEWS, DAVID R., PRATO, STEFANO DEL

“…Background: In the VERIFY study, early combination therapy with vildagliptin+metformin (V+M) reduced initial and secondary treatment failure (TF) as compared…”
Get full text

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies by Kozlovski, Plamen, Fonseca, Marilia, Mohan, Viswanathan, Lukashevich, Valentina, Odawara, Masato, Paldánius, Päivi M., Kothny, Wolfgang

“…Aims To determine the impact of race and ethnicity on the efficacy, body weight and hypoglycaemia incidence with vildagliptin treatment in patients with type 2…”
Get full text

The need for appropriate registration of pregnancy outcomes under newer oral glucose‐lowering therapies by Benhalima, Katrien, Mathiesen, Elisabeth R., Paldanius, Päivi M., Mathieu, Chantal

“…Because of the increase in type 2 diabetes (T2DM) in young adults, women of childbearing age are frequently treated with newer glucose‐lowering therapies, and…”
Get full text

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial by Matthews, David R, Paldánius, Päivi M, Proot, Pieter, Chiang, YannTong, Stumvoll, Michael, Del Prato, Stefano

“…Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy…”
Get full text

Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study by Vencio, Sérgio, Manosalva, Juan P, Mathieu, Chantal, Proot, Pieter, Lozno, Hernan Yupanqui, Paldánius, Päivi M

“…Abstract Background Patients with type 2 diabetes mellitus (T2DM) from Latin American countries face challenges in access to healthcare, leading to…”
Get full text

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus by Yoo, Soon-Jib, Chang, Sang-Ah, Sohn, Tae Seo, Kwon, Hyuk-Sang, Lee, Jong Min, Moon, Sungdae, Proot, Pieter, Paldánius, Päivi M, Yoon, Kun Ho

“…We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type…”
Get full text

Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study by Strain, W David, Agarwal, Abhijit S, Paldánius, Päivi M

“…We tested the feasibility of setting individualized glycemic goals and factors influencing targets set in a clinical trial in elderly patients with type 2…”
Get full text

Serum and Urinary Osteocalcin in Healthy 7- to 19-Year-Old Finnish Children and Adolescents by Paldánius, Päivi M., Ivaska, Kaisa K., Mäkitie, Outi, Viljakainen, Heli

“…Children and adolescents have high bone turnover marker (BTM) levels due to high growth velocity and rapid bone turnover. Pediatric normative values for BTMs…”
Get full text

Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes by Vencio, Sérgio, Paldánius, Päivi M, Blüher, Matthias, Giannella-Neto, Daniel, Caiado-Vencio, Rafael, Strain, W David

“…Type 2 diabetes mellitus (T2DM) is a complex disease, particularly in a continental country like Brazil. We attempted to understand and evaluate the…”
Get full text

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis by Brath, Helmut, Paldánius, Päivi M., Bader, Giovanni, Mathieu, Chantal

“…Introduction To assess the impact of duration of type 2 diabetes on glucose-lowering effectiveness of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin…”
Get full text

Total and carboxylated osteocalcin associate with insulin levels in young adults born with normal or very low birth weight by Paldánius, Päivi M, Ivaska, Kaisa K, Hovi, Petteri, Andersson, Sture, Eriksson, Johan G, Väänänen, Kalervo, Kajantie, Eero, Mäkitie, Outi

“…Osteocalcin (OC), a bone-derived protein, has been implicated in the regulation of glucose and energy metabolism. Young adults born with very low birth weight…”
Get full text

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment by Thomas, Merlin C., Paldánius, Päivi M., Ayyagari, Rajeev, Ong, Siew Hwa, Groop, Per-Henrik

“…Introduction Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in the management of patients with type 2 diabetes mellitus (T2DM) and renal impairment…”
Get full text

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus by Evans, Marc, Kozlovski, Plamen, Paldánius, Päivi M., Foley, James E., Bhosekar, Vaishali, Serban, Carmen, Avogaro, Angelo

“…Introduction In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs,…”
Get full text

1276-P: Effect of Trial Participation on Metabolic Parameters in People with Progressive Diabetic Complications by PALDÁNIUS, PÄIVI M., STRAIN, WILLIAM D.

“…Multiple randomized controlled trials (RCTs) in people with diabetes have demonstrated a substantial placebo effect, as a result of enhanced patient-physician…”
Get full text